Uzbekistan will develop a roadmap and long-term strategy for the advancement of nuclear medicine, according to the press service of the Atomic Energy Agency under the Cabinet of Ministers, Uzatom.
The announcement followed a working meeting held on February 10 at Uzatom to discuss prospects for expanding nuclear medicine in the country. The meeting brought together representatives of the Ministry of Health, the Healthcare Projects Center, the Committee for Industrial, Radiation and Nuclear Safety, the Institute of Nuclear Physics of the Academy of Sciences, the state enterprise Radiopreparat, leading medical centers, and experts from Rosatom’s engineering division, underscoring growing cooperation between Uzbekistan and Russia in the sector.
During the discussions, the Russian side presented its experience in building modern nuclear medicine infrastructure, including cyclotron complexes, radiopharmaceutical production facilities, and PET/CT diagnostic centers, as well as implementing turnkey international projects.
Following the talks, the parties agreed to jointly draft a roadmap and strategy that will provide a framework for technology transfer, specialist training, and improvements in healthcare services. The initiative is intended to strengthen early cancer diagnosis and expand access to advanced treatment methods based on nuclear technologies.
The construction of a Nuclear Medicine Center in Tashkent has begun. The center is scheduled to be equipped in 2026 with PET/CT scanners, a cyclotron, a radiopharmaceutical laboratory, as well as Gamma Knife and CyberKnife systems. The broader program also involves upgrading oncology services, promoting early cancer detection, training medical personnel to international standards, and deepening cooperation with Russia and Rosatom.
Uzatom stated that it will continue to support the introduction of advanced technologies aimed at improving access to modern cancer diagnostics and treatment.
As previously reported by The Times of Central Asia, citing IQVIA data, Uzbekistan’s pharmaceutical market reached $2.14 billion in the twelve months to September 2025, reflecting continued expansion and rising demand for medical services.
